Clinical Trial Update: A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical study evaluating CT1390B for relapsed/refractory acute myeloid leukemia is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CT1390B

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory Acute Myeloid Leukemia(AML) | Phase 1 | Status: NOT_YET_RECRUITING